出血性疾病治療市場規模、佔有率及成長分析（按藥物類型、疾病類型、給藥途徑、最終用戶和地區）－2025 年至 2032 年產業預測

出血性疾病治療市場規模預計到 2023 年將達到 162.6 億美元，從 2024 年的 176.6 億美元成長到 2032 年的 341.7 億美元，預測期內（2025-2032 年）的複合年成長率為 8.6%。

由於幾個關鍵因素，全球出血性疾病治療市場正在經歷顯著成長。A型血友病 A和 B、血管性血友病等的盛行率不斷上升，導致對先進治療性介入的需求不斷增加。重組凝血因子和基因療法的發展等技術進步正在進一步推動市場擴張。儘管取得了這些進展，但挑戰依然存在，包括尖端治療費用高昂以及某些地區的治療機會有限。北美和歐洲憑藉其完善的醫療保健基礎設施和強大的研究舉措，目前佔據市場主導地位。亞太地區的新興經濟體也正在經歷由意識增強和醫療保健投資推動的成長。最近的發展凸顯了該領域的動態性質。 2023 年 2 月，美國FDA核准了ALTUVIIIO，這是一款用於治療A型血友病 A的First-in-Class、高長效 VIII 因子替代療法。此外，BioMarin 報告了其用於治療重度A型血友病 A 的基因療法 ROCTAVIAN 的 3 期試驗的積極結果。這些進展凸顯了預防性和創新治療的趨勢，並將塑造出血性疾病管理的未來模式。然而，要充分享受這些醫療創新的好處，解決成本障礙和確保公平取得醫療服務仍然至關重要。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局

出血性疾病治療市場規模（依藥物類型及複合年成長率）（2025-2032）

• 市場概覽
• 血漿來源的凝血因子濃縮物
• 重組凝血因子濃縮物
• 去氨加壓素
• 抗纖維溶解劑
• 纖維蛋白膠
• 其他

出血性疾病治療市場規模（依疾病類型及複合年成長率）（2025-2032）

• 市場概覽
• A型血友病A
• B型血友病
• 血管性血友病
• 肝病
• 其他

出血性疾病治療市場規模（依給藥途徑及複合年成長率）（2025-2032）

• 市場概覽
• 靜脈
• 皮下
• 口服

出血性疾病治療市場規模（按最終用戶和複合年成長率分類）（2025-2032）

• 市場概覽
• 醫院
• 診所
• 學術機構
• 居家照護

出血性疾病治療市場規模（依分銷管道分類）及複合年成長率（2025-2032）

• 市場概覽
• 醫院藥房
• 零售藥局
• 配藥藥房

出血性疾病治療市場規模：按地區及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較比較（2022-2024 年）

主要企業簡介

• AbbVie Inc.（USA）
• Bayer AG（Germany）
• Novo Nordisk A/S（Denmark）
• Pfizer Inc.（USA）
• Biogen（USA）
• CSL Behring（Australia）
• Grifols SA（Spain）
• Octapharma AG（Switzerland）
• BDI Pharma Inc.（USA）
• Sanofi（France）
• Takeda Pharmaceutical Company Limited（Japan）
• F. Hoffmann-La Roche AG（Switzerland）
• Amgen Inc.（USA）
• Baxter International Inc.（USA）
• BioMarin Pharmaceutical Inc.（USA）
• Genentech, Inc.（USA）
• Kedrion Biopharma Inc.（Italy）
• LFB SA（France）
• Kamada Ltd.（Israel）

結論和建議

Bleeding Disorders Treatment Market size was valued at USD 16.26 Billion in 2023 and is poised to grow from USD 17.66 Billion in 2024 to USD 34.17 Billion by 2032, growing at a CAGR of 8.6% during the forecast period (2025-2032).

The global market for bleeding disorders treatment is experiencing significant growth, driven by several key factors. The increasing prevalence of conditions such as hemophilia A and B, along with von Willebrand disease, has heightened the need for advanced therapeutic interventions. Technological advancements, including the development of recombinant clotting factors and gene therapies, are further propelling market expansion. Despite these advancements, challenges persist, notably the high costs associated with cutting-edge treatments and limited access in certain regions. North America and Europe currently dominate the market, attributed to their established healthcare infrastructures and robust research initiatives. Emerging economies in the Asia-Pacific region are also witnessing growth, driven by increasing awareness and healthcare investments. Recent developments highlight the dynamic nature of this field. In February 2023, the U.S. FDA approved ALTUVIIIO, a first-in-class, high-sustained factor VIII replacement therapy for hemophilia A, offering normal to near-normal factor activity levels with once-weekly dosing. Additionally, BioMarin Pharmaceutical reported positive results from a Phase 3 study of ROCTAVIAN, an investigational gene therapy for severe hemophilia A, indicating sustained efficacy over three years. These advancements underscore a trend towards prophylactic treatments and innovative therapies, shaping the future landscape of bleeding disorder management. However, addressing cost barriers and ensuring equitable access remain critical to fully realizing the benefits of these medical innovations.

Top-down and bottom-up approaches were used to estimate and validate the size of the Bleeding Disorders Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Bleeding Disorders Treatment Market Segments Analysis

Global Bleeding Disorders Treatment Market is segmented by Drug Type, Disease Type, Route of Administration, End User, Distribution Channel and region. Based on Drug Type, the market is segmented into Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Others. Based on Disease Type, the market is segmented into Hemophilia A, Hemophilia B, Von Willebrand Disease, Liver Disease and Others. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous and Oral. Based on End User, the market is segmented into Hospitals, Clinics, Academic Institutions and Homecare Settings. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Compounding Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Bleeding Disorders Treatment Market

The rising prevalence of bleeding disorders, such as hemophilia and von Willebrand disease (VWD), has led to an increased demand for advanced treatment options. VWD, for instance, affects up to 1% of the population, often going undiagnosed due to its variable symptoms. Technological advancements in hemostasis management, including the development of recombinant clotting factors and gene therapies, have resulted in more effective and targeted interventions. Innovations like the HemoSonic diagnostic device, which utilizes ultrasound technology to rapidly assess hemostasis, have received FDA approval for use in critical medical scenarios, enhancing patient outcomes.

Restraints in the Bleeding Disorders Treatment Market

The high costs associated with advanced treatments for bleeding disorders, such as hemophilia, present significant barriers to patient access, particularly in economically disadvantaged regions. For instance, gene therapies, while potentially curative, can cost up to $3.5 million per dose, placing a substantial financial strain on healthcare systems and patients. Additionally, regulatory complexities and lengthy approval processes hinder the swift introduction of innovative therapies. Challenges such as costly and restrictive clinical trials and outdated regulatory approval processes impede the advancement of new medical devices from research to clinical use.

Market Trends of the Bleeding Disorders Treatment Market

The increasing focus on personalized medicine aims to tailor treatments to individual patient profiles, optimizing efficacy and minimizing adverse effects. Advancements in gene therapy are emerging as transformative, with ongoing research and clinical trials showcasing the potential for curative approaches to certain bleeding disorders. Additionally, prophylactic treatments are gaining prominence, emphasizing the preventive management of bleeding episodes rather than reactive interventions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape

Global Bleeding Disorders Treatment Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Plasma-Derived Coagulation Factor Concentrates
• Recombinant Coagulation Factor Concentrates
• Desmopressin
• Antifibrinolytics
• Fibrin Sealants
• Others

Global Bleeding Disorders Treatment Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Liver Disease
• Others

Global Bleeding Disorders Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intravenous
• Subcutaneous
• Oral

Global Bleeding Disorders Treatment Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Academic Institutions
• Homecare Settings

Global Bleeding Disorders Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Compounding Pharmacies

Global Bleeding Disorders Treatment Market Size & CAGR (2025-2032)

• North America (Drug Type, Disease Type, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Disease Type, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Disease Type, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Disease Type, Route of Administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Disease Type, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BDI Pharma Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion Biopharma Inc. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kamada Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations